Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes Association meeting in New Orleans.

The Economic Times

Experts call for weight loss jabs to be investigated as cancer prevention

Experts from the US examined data on more than 161,000 patients

The Independent UK

Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy

Penn Medicine researchers report a 30% lower breast cancer risk in women using Ozempic and Wegovy, based on a study of 111,646 patients. Findings suggest GLP-1 drugs may play a role in cancer prevention, though experts stress results are observational.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

The Economic Times

Move Over, Ozempic: Scientists Unveiled a New Diabetes Pill That Burns Fat Without Killing Your Appetite — And It Could Be a Breakthrough for Millions of Americans

Researchers at Karolinska Institutet published a study showing a new oral compound activates muscle metabolism to lower blood sugar and torch fat — without nausea, muscle loss, or the side effects plaguing GLP-1 drugs.

Medical Daily

With Nation's Highest Diabetes Rate, San Antonio Faces Major Shift as Medicare Prepares $50 Wegovy Coverage

With diabetes rates among the highest in the U.S., San Antonio could see major change as Medicare's new $50 Wegovy coverage begins July 1, expanding access for eligible residents.

Medical Daily

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

Medical Daily

‘Morally unreasonable’ to tackle childhood obesity with weight loss jabs, Chris Whitty says

The 2024 Health Survey for England found that 15 per cent of children aged two to 15 were living with obesity

The Independent UK

Time to walk and cycle the talk: Unsafe roads and broken footpaths are worsening India’s obesity crisis

Commuting in Indian urban centers is riddled with obstacles, where inadequate sidewalks and hazardous road conditions push people towards cars, resulting in a rise in lifestyle-related health problems. Interestingly, a large number of city trips could easily be made by foot or bike, yet the lack of safe pathways keeps…

The Economic Times

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access…

The Economic Times

The Hidden Side Effect of Weight-Loss Injections That Men Aren’t Talking About

Weight-loss injections continue to reshape conversations around obesity treatment and metabolic health. Men across different age groups report rapid drops in appetite and steady weight loss that once felt difficult to achieve. Clinics highlight improvements in blood sugar control, waist size, and cardiovascular markers.

Clever Dude

Can Wegovy move the needle on NZ’s obesity crisis, or simply treat its symptoms?

Even before receiving public funding, Wegovy has drawn much media attention in New Zealand for the dramatic difference it can make for weight loss.

The Conversation

Donald Trump Weight Gain: CNN Expert Calls Out Discrepancies in Medical Memo

A new White House medical memo reveals Donald Trump has gained 14 pounds in a year, edging his BMI to the brink of obesity even as his doctor insists he is in 'excellent health'.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Donald Trump's BMI Nears Clinical Obesity In New Medical Report

Donald Trump's recent medical report shows a BMI of 29.7, sparking discussions about his weight and health, despite claims of being in 'excellent health' by his physician.

International Business Times UK

Donald Trump's BMI Nears Clinical Obesity as New Medical Report Sparks Health Alarm

Donald Trump's recent medical report shows a BMI of 29.7, sparking discussions about his weight and health, despite claims of being in 'excellent health' by his physician.

Euronews

Exercise less, burn more fat: Scientists unveil a simple method for weekly weight loss

New research from scientists in Hong Kong suggests you don’t necessarily need daily workouts or high‑repetition training to cut belly fat.

The Independent UK

New research finds link between obesity and breast cancer risks

Some 321,910 new cases of invasive breast cancer are estimated to be diagnosed this year

Get all your
news in one place.

100's of premium titles.
One news app.

MyLifeXP

India’s GLP-1 Weight Loss Drug Problem Nobody Is Warning You About

A 26-year-old marketing executive in Mumbai loses 14 kilos in three months. Her Instagram fills with compliments. Friends ask for her “secret.” She smiles and says it is just discipline and calorie control. What she does not mention is the weekly injection sitting inside her refrigerator. Across India, GLP-1 drugs…

Medical Daily

Understanding Visceral Fat Health and Why Belly Fat Is a Serious Obesity Risk

Learn how visceral fat differs from subcutaneous fat, why belly fat increases obesity risk, and how improving visceral fat health supports long term disease prevention.

Euronews

Greece becomes a model country against childhood obesity with UNICEF's help

The results of the initiatives in Greece to tackle childhood obesity have been presented, showing outstanding progress.

The Guardian - UK

The Guardian view on support for youth: someone in government should grab hold of school sports

Editorial: With concerns about childhood obesity and screen use sky-high, cuts to primary PE are an unforced error

Budget and the Bees

GLP‑1 Weight-Loss Pill Launches: Oral Options Like Wegovy Could Make Injections Obsolete

For years, GLP-1 drugs like Wegovy and Ozempic transformed weight management, but they came with one major drawback: injections. That barrier kept many people from even asking their doctor about treatment. Now, the rise of the oral GLP-1 weight-loss pill is changing the conversation in a big way. With daily…

International Business Times UK

The Cost and Consequences of GLP-1 Agonists: Are They Worth the Long-Term Investment?

Shedding light on the advantages and disadvantages of continued use of GLP-1 agonists for users.

Saving Advice

GLP-1 Coverage Update: How Medicare’s New Transitional Policies Could Lower Out-of-Pocket Costs for Weight-Loss Medications

For years, many seniors and retirees have faced a frustrating reality: popular GLP-1 medications like Wegovy and Zepbound could cost well over $1,000 per month...

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.